Principal Financial Group Inc. Takes Position in Harrow, Inc. (NASDAQ:HROW)

Principal Financial Group Inc. bought a new position in shares of Harrow, Inc. (NASDAQ:HROW) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 7,320 shares of the company’s stock, valued at approximately $329,000.

Several other institutional investors also recently modified their holdings of HROW. Quest Partners LLC acquired a new stake in shares of Harrow in the third quarter valued at approximately $29,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Harrow by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company’s stock worth $57,000 after purchasing an additional 227 shares during the period. Allspring Global Investments Holdings LLC increased its position in shares of Harrow by 2,730.7% in the second quarter. Allspring Global Investments Holdings LLC now owns 2,123 shares of the company’s stock worth $44,000 after purchasing an additional 2,048 shares during the period. Hills Bank & Trust Co bought a new position in Harrow in the third quarter valued at approximately $107,000. Finally, Huntington National Bank acquired a new position in shares of Harrow during the 3rd quarter worth $164,000. 72.76% of the stock is currently owned by institutional investors and hedge funds.

Harrow Price Performance

HROW opened at $35.96 on Tuesday. Harrow, Inc. has a fifty-two week low of $9.13 and a fifty-two week high of $59.23. The firm has a 50-day moving average of $40.31 and a 200 day moving average of $38.06. The firm has a market cap of $1.28 billion, a P/E ratio of -38.26 and a beta of 0.72. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. B. Riley cut their price objective on Harrow from $73.00 to $69.00 and set a “buy” rating on the stock in a report on Wednesday, December 4th. Lake Street Capital raised their target price on Harrow from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Friday, October 4th. Finally, Craig Hallum raised their price target on shares of Harrow from $45.00 to $65.00 and gave the company a “buy” rating in a research report on Friday, October 4th.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.